Home › U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen
 

Keywords :   


U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

2015-03-19 22:40:00| Biotech - Topix.net

A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first biosimilar in the United States.

Tags: block bid judge rejects

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Atlantic Tropical Weather Outlook
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Forecast Discussion Number 25
04.07Hurricane Beryl Public Advisory Number 25
04.07Summary for Hurricane Beryl (AT2/AL022024)
04.07Hurricane Beryl Wind Speed Probabilities Number 25
04.07Hurricane Beryl Forecast Advisory Number 25
More »